Back to Search
Start Over
The endocannabinoid receptors CB1 and CB2 affect the regenerative potential of adipose tissue MSCs.
- Source :
-
Experimental cell research [Exp Cell Res] 2020 Apr 01; Vol. 389 (1), pp. 111881. Date of Electronic Publication: 2020 Jan 29. - Publication Year :
- 2020
-
Abstract
- Human adipose tissue includes large quantities of mesenchymal stromal cells (atMSCs), which represent an abundant cell source for therapeutic applications in the field of regenerative medicine. Adipose tissue secrets various soluble factors including endocannabinoids, and atMSCs express the cannabinoid receptors CB1 and CB2. This indicates that adipose tissue possesses an endocannabinoid system (ECS). The ECS is also ascribed great significance for wound repair, e.g. by modulating inflammation. However, the exact effects of CB1/CB2 activation in human atMSCs have not been investigated, yet. In the present study, we stimulated human atMSCs with increasing concentrations (1-30 μM) of the unspecific cannabinoid receptor ligand WIN55,212-2 and the specific CB2 agonist JWH-133, either alone or co-applied with the receptor antagonist Rimonabant (CB1) or AM 630 (CB2). We investigated the effects on metabolic activity, cell number, differentiation and cytokine release, which are important processes during tissue regeneration. WIN decreased metabolic activity and cell number, which was reversed by Rimonabant. This suggests a CB1 dependent mechanism, whereas the number of atMSCs was increased after CB2 ligation. WIN and JWH increased the release of VEGF, TGF-β1 and HGF. Adipogenesis was enhanced by WIN, which could be reversed by blocking CB1. There was no effect on osteogenesis, and only WIN increased chondrogenic differentiation. Our results indicate that definite activation of the cannabinoid receptors exerted different effects in atMSCs, which could be of specific value in cell-based therapy for wound regeneration.<br />Competing Interests: Declaration of competing interest No potential conflicts of interest, financial or otherwise are declared by the authors. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.<br /> (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Subjects :
- Benzoxazines pharmacology
Cannabinoids pharmacology
Cell Differentiation drug effects
Cells, Cultured
Cytokines metabolism
Dose-Response Relationship, Drug
Endocannabinoids agonists
Endocannabinoids antagonists & inhibitors
Endocannabinoids pharmacology
Humans
Indoles pharmacology
Intercellular Signaling Peptides and Proteins metabolism
Mesenchymal Stem Cells cytology
Mesenchymal Stem Cells drug effects
Morpholines pharmacology
Naphthalenes pharmacology
Primary Cell Culture
Receptor, Cannabinoid, CB1 agonists
Receptor, Cannabinoid, CB1 antagonists & inhibitors
Receptor, Cannabinoid, CB2 agonists
Receptor, Cannabinoid, CB2 antagonists & inhibitors
Rimonabant pharmacology
Adipose Tissue cytology
Cell Self Renewal drug effects
Mesenchymal Stem Cells physiology
Receptor, Cannabinoid, CB1 physiology
Receptor, Cannabinoid, CB2 physiology
Regeneration drug effects
Regeneration physiology
Subjects
Details
- Language :
- English
- ISSN :
- 1090-2422
- Volume :
- 389
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Experimental cell research
- Publication Type :
- Academic Journal
- Accession number :
- 32006556
- Full Text :
- https://doi.org/10.1016/j.yexcr.2020.111881